Friday, August 3, 2018

Here's how much money you could be losing by avoiding the stock market

Having too much money in the bank is a problem that millions of Americans would love to have. But those fortunate enough to be in that position may be making a big financial mistake with their cash.

A new survey from Nerdwallet shows that while many Americans have little to no savings, the average American keeps $32,000 in cash. Keeping so much money in the bank could mean missing out on the potential rewards that come with investing that money.

For long-term goals like retirement, interest rates on savings may not even be keeping up with inflation.

"People keep money in cash because they want something that's guaranteed," says Erik Davidson, Chief Investment Officer at Wells Fargo. "They don't want to lose money. But after taxes and inflation, you're actually losing money."

Plus, you're missing out on some serious upside potential. The Nerdwallet analysis found that keeping that money in the bank rather than investing it could mean cost you $140,000 worth of returns over 30 years (assuming a 6% return from stocks vs. a 1% return on savings).

For long-term growth, most financial professionals agree that you need a diversified portfolio that includes stocks and bonds. Here's how to get started:

Open a retirement account

If you have access to an employer-sponsored retirement account, that's the easiest way to begin investing in the stock market. Of employers who offer a retirement plan, 76% will match some of your savings. If that's the case with your company, you should be investing at least enough to get the match.

"If you're not saving enough to get the employer match, you're leaving money on the table," says Jim Benedict, a certified financial planner and senior wealth strategist at PNC Wealth Management.

If you don't have access to a retirement plan at work, you can still get the tax benefits of putting money into a retirement account by opening an IRA or a Roth IRA on your own.

Keep it simple

Choosing investments can feel overwhelming, but there are lots of tools that can help. Your plan likely offers an online asset allocation calculator, which can help you determine how much of your portfolio you should put into stocks and how much should go into bonds or other investments, based on your time horizon and tolerance for risk. If that feels like too much, look for a target-date fund, which will automatically put your money into a mix of investments tied to your retirement date and take care of rebalancing for you as that date approaches.

Stay the course

While the stock market has been marching steadily upward for nearly a decade, it's going to fluctuate. At some point you will have periods of major losses. As long as you don't need your money immediately, there's no reason to stress over such movement. Check on your portfolio once or twice a year to make sure your allocations still fit with your long-term plan, but resist the urge to buy or sell based on recent market movements. And remember that such ups and downs are a normal part of investing.

"Don't panic and liquidate if you're down in a year, because you've got several years to recoup that back," says Derek Green, wealth advisor at Titus Wealth Management. "The best thing to do is to keep dollar-cost averaging and buying. Then when the rebound comes you'll be even better off."

Thursday, August 2, 2018

Hot Biotech Stocks For 2019

tags:PLUG,FDP,VNCE,

Utility companies aren't usually fan favorites among investors, but these protected and counter-cyclical companies are my favorites for a long-term portfolio. Consistent cash flow means high dividend yields and sales don't fluctuate like in other industries.

---Recommended Link--- This Tiny Biotech Is Set To Disrupt A $133� Billion Market
It's like something straight out of science-fiction... According to our research, the U.S. Army has invested in a small biotech company with a breakthrough technology using the DNA of spiders. We're not kidding. Not only could it change the future of warfare -- it has a host of unique properties that could lead to a range of applications, allowing early investors to strike it rich. To get all the fascinating details, go here.

But rising rates are weighing on utilities and inflation could start to eat into profits for regulated producers. The Utilities Select Sector SPDR (NYSE: XLU) is up just 0.6% over the last year, lagging the broader market by nearly 13% over the 12 months.

Hot Biotech Stocks For 2019: Plug Power Inc.(PLUG)

Advisors' Opinion:
  • [By Paul Ausick]

    Plug Power Inc. (NASDAQ: PLUG) saw short interest dip by 0.2% to 34.41 million shares. Days to cover remained unchanged at 10, and about 15.2% of the company’s shares were short. In the two weeks to April 30, the share price fell by about 3.2%. The stock’s 52-week range is $1.53 to $3.21, and shares closed Wednesday at $2.00, up about 8.7% for the day.

  • [By Peter Graham]

    A long term performance chart shows shares of FuelCell Energy severely underperforming while�small cap alternative energy or fuel cell stocks like Ballard Power Systems Inc (NASDAQ: BLDP), Hydrogenics Corporation (NASDAQ: HYGS) and Plug Power Inc (NASDAQ: PLUG) all peaked in 2014 with some of them showing signs of stabilization and�some�positive growth last year:

  • [By Paul Ausick]

    Plug Power Inc. (NASDAQ: PLUG) saw short interest rise by 3.1% to 37.61 million shares. Days to cover rose from eight to 12. In the two weeks to June 15, the share price rose by nearly 3%. The stock’s 52-week range is $1.53 to $3.21, and shares closed most recently at $2.03, up about 4.6% for the day.

  • [By Paul Ausick]

    Plug Power Inc. (NASDAQ: PLUG) saw short interest dip by 7.5% to 34.81 million shares. Days to cover remained unchanged at 12, and about 16.5% of the company’s shares were short. In the final two weeks of June, the share price rose by 2.5%. The stock’s 52-week range is $1.53 to $3.21, and shares closed Wednesday at $2.06, flat for the day.

  • [By Maxx Chatsko]

    Shares of Plug Power Inc. (NASDAQ:PLUG) certainly acted that way following the release of the company's first-quarter 2018 operating results. Year-over-year revenue growth of 91% is pretty difficult to argue with, and management thinks second-quarter 2018 sales will grow by at least 60% from the prior-year period. All in all, it's shaping up to be a great year for top-line growth.

Hot Biotech Stocks For 2019: Fresh Del Monte Produce, Inc.(FDP)

Advisors' Opinion:
  • [By Shane Hupp]

    Dean Investment Associates LLC raised its stake in Fresh Del Monte Produce (NYSE:FDP) by 17.9% during the first quarter, HoldingsChannel.com reports. The fund owned 94,185 shares of the company’s stock after acquiring an additional 14,270 shares during the quarter. Dean Investment Associates LLC’s holdings in Fresh Del Monte Produce were worth $4,261,000 at the end of the most recent reporting period.

  • [By Stephan Byrd]

    Fresh Del Monte Produce (NYSE: FDP) and Limoneira (NASDAQ:LMNR) are both consumer staples companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation and analyst recommendations.

  • [By Ethan Ryder]

    Alico (NASDAQ: ALCO) and Fresh Del Monte Produce (NYSE:FDP) are both consumer staples companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, risk and institutional ownership.

Hot Biotech Stocks For 2019: Vince Holding Corp.(VNCE)

Advisors' Opinion:
  • [By Shane Hupp]

    Francesca’s (NASDAQ: FRAN) and Vince (NYSE:VNCE) are both small-cap consumer discretionary companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

  • [By Lisa Levin] Gainers Oragenics, Inc. (NYSE: OGEN) shares surged 66.67 percent to close at $2.00 on Wednesday after the company’s AG013 for oral mucositis in head and neck cancer patients showed favorable safety profile in mid-stage OM study. Sigma Labs, Inc. (NASDAQ: SGLB) shares jumped 49.24 percent to close at $1.97 on Wednesday. Sigma Labs demonstrated proof of concept for closed loop quality control during metal additive manufacturing. ASLAN Pharmaceuticals Limited (NASDAQ: ASLN) rose 34.45 percent to close at $9.21. BTIG Research initiated coverage on ASLAN Pharmaceuticals with a Buy rating. Dick's Sporting Goods, Inc. (NYSE: DKS) shares rose 25.82 percent to close at $38.35 after the company reported upbeat Q1 earnings and raised FY18 earnings outlook. TapImmune, Inc. (NASDAQ: TPIV) rose 24.15 percent to close at $5.09. WBB Securities upgraded TapImmune from Speculative Buy to Buy. Legacy Reserves LP (NASDAQ: LGCY) jumped 23.3 percent to close at $5.98 on Wednesday. Summer Infant, Inc. (NASDAQ: SUMR) gained 22.92 percent to close at $1.18 after announcing commitment for $60 million credit facility from Bank of America and $17.5 million term loan from Pathlight Capital. Cloud Peak Energy Inc. (NYSE: CLD) rose 21.95 percent to close at $4.00. SpartanNash Co (NASDAQ: SPTN) gained 21.4 percent to close at $22.92 after the company reported upbeat earnings for its first quarter on Tuesday. Motus GI Holdings, Inc. (NASDAQ: MOTS) rose 17.14 percent to close at $5.40. Movado Group, Inc. (NYSE: MOV) gained 16.59 percent to close at $49.20 after the company reported better-than-expected Q1 results and raised its guidance. Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) climbed 15.61 percent to close at $8.22. Oramed Pharma disclosed that its patent has been allowed in the US for oral administration of proteins. Dorian LPG Ltd. (NYSE: LPG) rose 14.89 percent to close at $8.41. Dorian LPG confirmed receipt of unsolicited proposal fr